drug
trastuzumab
Marketedupdated 3mo agoby Genentech Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval64 co-mentions · 32 sources
- drugtrastuzumab deruxtecan39 co-mentions · 13 sources
- drugKADCYLA28 co-mentions · 14 sources
- drugtrastuzumab emtansine28 co-mentions · 14 sources
- drugENHERTU26 co-mentions · 13 sources
- drugtrastuzumab biosimilar21 co-mentions · 21 sources
- tagBreast Cancer11 co-mentions · 2 sources
- drugONTRUZANT10 co-mentions · 5 sources
all catalysts(0)
nothing on the calendar yet
Trials studying trastuzumab
- phase2A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
- phase2Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- phase3DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- phase3A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- phase2Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
- phase1A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
- phase3Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
- phase3A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
News(10)
- After 5-month wait, BioNTech announces Sobi CEO will take on top job at mRNA companyOne of the most closely watched vacancies in biopharma has now been filled, with Sobi CEO Guido Oelkers, Ph.D., moving across to take up the top job at mRNA pioneer BioNTech.fiercebiotech · 14d ago
- A Spanish biotech banks $87M to make differentiated ADCsOna Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced forms of breast and colorectal cancers.biopharma_dive · 2mo ago
- FDA Approves T-DXd for Early-Stage HER2+ Breast CancerThe FDA approved trastuzumab deruxtecan for the adjuvant and neoadjuvant treatment of select early-stage HER2-positive breast cancer.onclive · 3mo ago
- Honesty and Humor Provide Hope in Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Annie BondDr Nunnery and Annie Bond discuss breast cancer survivorship and patient advocacy.onclive · 3mo ago
- Sequencing ADCs in Endometrial CancerSequencing therapy in recurrent endometrial cancer is becoming more complicated as immunotherapy moves earlier and antibody drug conjugates gain momentum.onclive · 3mo ago
- Dr Silbermann on Clinical Trial Design Considerations in Multiple MyelomaRebecca Silbermann, MD, MMS, outlines key trial design considerations in multiple myeloma, including supportive care measures and end point selection.onclive · 3mo ago
- MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine TumorsRoswell Park Comprehensive Cancer Center launched a phase 2 trial evaluating SurVaxM plus temozolomide in progressing neuroendocrine tumors.onclive · 3mo ago
- Dr Randall on the Rationale for Investigating CSF-1R Inhibition in TGCTR. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.onclive · 3mo ago
- RAPNO Criteria and MRI Assessment in PLGG: Recommendations vs. Real-World PracticeLearn how clinicians weigh symptoms, MRI changes and family goals to decide when a child’s tumor needs treatment—beyond simple size cutoffs.onclive · 3mo ago
- Expanding ctDNA Applications to RCC and Germ Cell TumorsExperts explain how ctDNA tracking in metastatic cancer guides therapy tweaks, flags relapse early, and where it fails in brain/peritoneal disease.onclive · 3mo ago
Data sources
last refreshed 52m ago
Found something off?
comments(0)
5-min edit window · permanent after that